🔗 Share this article

While the US proceeds with sweeping adjustments to its vaccination guidelines, one figure has emerged unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccines in the global health crisis and has concentrated on potential deaths following COVID-19 immunization in her recent time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Agency leaders planned to announce radical changes to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, sources say – a major change that would place the US at odds with a large portion of the international standard with insufficient data for public health gain. This reveal has been delayed until the next year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with nationalized medicine and a population approximately the population of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – usually the purview of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Expertise

Høeg has no apparent track record in medication creation, oversight or administrative roles, which has been customary for past heads of the CBER. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in industry regulation.”

Former directors of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran CBER have had.”

The drug center has an vast portfolio at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic program approves thousands of generic medications. There’s a biosimilars program, OTC medication office and so forth, and all of those need to be managed,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative aspect to the job, which manages over 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” Woodcock concluded.

Official Statement and Controversial Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection represents more teamwork among agency officials on immunizations, a press secretary stated that the “questions rely on inaccurate assumptions”.

“Her resume matches the functions of her position,” the representative said, pointing to the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a contentious expedited drug-approval program that allegedly worried her former heads. “How are these therapies being selected for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards laxer regulations of most medications, with the exception of immunizations.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if troubling, past, some experts said. She published a analysis using non-validated public submissions to assess the frequency of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new federal leadership featured changing guidelines for novel immunizations and ending “optional” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing young men from obtaining Covid vaccines.

“She is an all-around true believer who begins with her beliefs and tailors the evidence to accommodate the evidence in a extremely disingenuous, untruthful manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|